MedTrace Logo

Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis

NCT02015520 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2021-05-12

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to identify an appropriate dose of study medication.

Conditions

Interventions

DRUG

Clazakizumab

DRUG

Placebo (Matching with Clazakizumab)

Sponsors & Collaborators

  • CSL Behring

    lead INDUSTRY

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2013-06-30
Completion
2015-06-30

Countries

  • United States
  • Argentina
  • Canada
  • France
  • Hungary
  • Italy
  • Japan
  • Mexico
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02015520 on ClinicalTrials.gov